CureVac is pioneering the therapeutic application of messenger RNA (mRNA), opening up an entirely novel class of drugs.
The Company's approach is based on its discovery that when stabilized, the direct application of mRNA via injection can lead to the expression of functional proteins.

NEWS & EVENTS

2008-02-29
Consortium Application of CureVac Chosen within the Development Initiative of the Federal Ministry of Education and Research “BioPharma” pfeil

Konsortialantrag der CureVac im Rahmen der Förderinitiative „BioPharma“ des BMBF ausgewählt pfeil

DOWNLOADS

CureVac at a glance

Company Profile

Firmenprofil